Breast cancer and neoadjuvant therapy: any predictive marker?

Area of Science:

• Oncology
• Medical Biochemistry

Background:

• Neoadjuvant chemotherapy is increasingly used for breast cancer, but predicting treatment response remains challenging.
• Identifying tumor characteristics that predict therapeutic response and patient outcome is of significant clinical interest.

Purpose of the Study:

• To evaluate the predictive power of tumor markers (CEA, Ca 15-3, ER/PR) for event-free survival (EFS) in breast cancer patients receiving neoadjuvant therapy.
• To identify histological and molecular tumor characteristics associated with therapeutic response and outcome.

Main Methods:

• Studied 141 breast carcinoma patients receiving neoadjuvant chemotherapy and/or radiotherapy.
• Assessed pathological response, histological and molecular tumor characteristics (steroid receptors, CEA, Ca 15-3) before and after therapy.
• Analyzed event-free survival (EFS) and therapeutic response using ROC analysis to determine cut-off points for markers.

Main Results:

• Therapeutic response was independent of investigated molecular parameters, but Ca 15-3, CEA, and ER/PR showed strong predictive associations with EFS.
• Specific cut-off points for Ca 15-3 (<23.0 kU/l), CEA (<5.0 mg/l), and ER (>5.0 fmol/mg) were associated with significantly better EFS.
• Tumor size (T2) and stage (II) were predictive of immediate therapeutic response and EFS.

Conclusions:

• Tumor markers Ca 15-3, CEA, and ER/PR are valuable predictors of event-free survival in breast cancer patients undergoing neoadjuvant therapy.
• Established diagnostically valuable cut-off points for these markers, aiding in prospective evaluation of neoadjuvant therapy.
• Tumor size and stage are also important factors influencing therapeutic response and patient outcomes.